



To: Sehgal Path Lab Private Limited

103, Yashodhan Bldg 2, Four Bungalows,

Andheri West Mumbai- 400053 Maharashtra

Report Of: Mrs. SUFIYA SHEIKH MAJID



Sample ID : 2400084962 Patient ID : 1002425097

Collected on: 24-05-2024

Received on: 27-05-2024 17:00:00 Reported on: 12-06-2024 05:39:09

Ref By Sehgal Path Lab Private

Limited

## **CONVENTIONAL KARYOTYPING REPORT**

Patient Name : Mrs. SUFIYA SHEIKH MAJID Age : 68 Years

Physician Name : - Gender : Female

Provisional : Pancytopenia under Specimen : Ok

Diagnosis evaluation Status

Specimen Type : Bone Marrow Aspirate (BMA) Disease Status: At Diagnosis

Test Requested : Conventional Karyotype

Test : Conventional Karyotype Analysis.

Method : 24-48 hr unstimulated culture of bone marrow aspirate followed

by metaphase cells preparation, GTG Banding, karyotype

analysis.

No. of Metaphase Cells

Analyzed : 20

No. of Metaphase Cells

karyotyped : 20

**Result** : 46,XX[20]

**ISCN** : 2020

**Band Resolution** : 350

**Interpretation:** Conventional Karyotype analysis revealed normal diploid female karyotype 46,XX in all 20 cells.






Mrs. SUFIYA SHEIKH MAJID

Sample ID: 2400084962

## **References:**

- 1. Mitelman F, Johansson B, Mertens F (eds). Mitelman Database of Chromosome Aberrations and G ene Fusions in Cancer,2013, http://cgap.nci.nih.gov/Chromosomes/Mitelman.
- 2. Daniel A. Arber, Attilio Orazi, Robert Hasserjian, Jurgen Thiele, et al.The 2016revision to the Worl d Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391-2 405, 2016; doi: https://doi.org/10.1182/blood-2016- 03-643544.
- 3. Steven H. Swerdlow, Elias Campo, et al.THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICA L MALIGNANCIES. The 2016 revision of the World Health Organization classification of lymphoid n eoplasms. Blood. 2016;127(20):2375-2390.



46,XX





## Mrs. SUFIYA SHEIKH MAJID

Sample ID: 2400084962

Prepared By: Snehal Kaskar

Verified By : Dr. Hrushikesh Lele

108Amose

Dr. P. S. Kadam Amare Oncogeneticist Chief & Lab Director "Cancer & Clinical Genetics" Lilac Insights Pvt. Ltd.

Dr. Hrushikesh Lele Sr. Scientific Officer Oncocytogenetics Dept.

Lilac Insights Pvt. Ltd.

- End of Report -

## Conditions of Reporting/Disclaimer:

- The report relates only to the specimen submitted to the lab which was verified and confirmed at the time of specimen collection. Also it is presumed that the specimen belongs to the patient named or identified, such verification being carried out at the point of generation of the said specimen.
- Although Conventional karyotyping is a gold standard method of cytogenetics which gives a global whole genomic view of
  multiple known, unknown chromosomal abnormalities, small cryptic, subtle aberrations below 7-8 Mb resolution can be
  missed.
- In spite of known sensitivity and efficiency of the genetic test, the test results have to be correlated with other clinical and pathological finding for conclusive diagnosis and disease management.
- A test request may be revised or generated by Lilac geneticist with an intimation to an Oncologist if: 1) Incomplete requisition 2) After haematopathology Update.
- In 1-2 % of APL cases, FISH may turn out to be negative due to PML/RARA probe design which unable to detect cryptic insertion of PML to RARA. In such rare cases, It is advisable to check PML-RARA by molecular methods.
- In case of Multiple Myeloma, flowcytometry report indicating abnormal plasma cell population is important for reference, as small abnormal clones may get deduced as per limit of detection policy in FISH analysis.
- In case of FFPE FISH, if H & E stained slides &/or histopathology report is not provided by customer, LILAC proceed with H & E staining followed by histopathology remarks along with marking of tumor area by our consultant pathologist.
- Assays are performed in accordance with standard procedure on receipt. The reported results are dependent on individual assay methods, equipment used, method specificity, sensitivity and quality of specimen(s) received.
- Lilac Insights Pvt. Ltd. has policy to return the FFPE blocks within one month after final reporting with proper documentation of the dispatch of the block to customer from accession dept, Lilac. After dispatch, if there is no intimation from customer within two weeks, Lilac will not be responsible for the Dispatched FFPE block.
- Soft copies of oncocytogenetics reports are sent to customer by office mail ID. Also, Hardcopies are sent to customer only on the address provided by client.